JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

The Journal of Nuclear Medicine Vol. 15 No. 9 743-749
© 1974 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Enlander, D.
Right arrow Articles by dos Remedios, L. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Enlander, D.
Right arrow Articles by dos Remedios, L. V.

Renal Cortical Imaging in 35 Patients: Superior Quality with 99mTc-DMSA

Derek Enlander, Paul M. Weber and Leo V. dos Remedios

Kaiser-Permanente Medical Center, Oakland, California

Correspondence: For reprints contact: Paul M. Weber, 280 W. MacArthur Blvd., Oakland, Calif. 94611.

ABSTRACT

The metal chelate 2,3-dimercaptosuccinic acid (DMSA) complexed with 99mTc appears to be a superior and safe renal scintigraphic agent, regularly revealing corticomedullary morphology with either a multihole or a pinhole collimator. Fifty percent or more of administered dose is retained by the renal cortex at 1 hr—the highest proportion that has been reported for any 99mTc complex. Scintiphotos of a variety of renal diseases and preliminary kinetic data are presented.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1974 by the Society of Nuclear Medicine.